Skip to main content

Mount Sinai Spinout Oova, Thorne Research Partner to Pilot At-Home Tool for Fertility Mapping

NEW YORK (360Dx) – Mount Sinai Health System said today that its spinout Oova is piloting a fertility monitoring tool through a partnership with Thorne Research.

The partnership will make Oova's product available to more than 3 million potential customers and 35,000 clinicians through bundled sales with Thorne supplements, Mount Sinai said.

Oova's technology provides an approach for women to measure and monitor the concentration of luteinizing hormone and progesterone — two key fertility markers. The at-home diagnostic tool consists of a paper-based test strip embedded with biochemistry that measures the amounts of these key hormones present in a urine sample. The strip is scanned and interpreted using the combination of a smartphone camera and artificial intelligence. 

The system will track daily hormone levels to predict peak fertility, monitor changes over time, and provide goal-based recommendations, Mount Sinai said.

Oova Cofounder and CTO Jerome Scelza said in a statement that by using its monitoring tool, women can acquire results in real time and will get access to personalized reproductive health data.

The technology also serves as a prognostic tool for fertility issues and polycystic ovary syndrome, and as a detection tool for cycle management, post-pregnancy menstrual assessment, and pre-menopause, Mount Sinai said. 

The Oova team consists of colleagues from the Institute for Next Generation Healthcare at the Icahn School of Medicine at Mount Sinai.

The spinout expects to launch its monitoring tool in the third quarter of this year.